Expression of the Pseudorabies Virus gB Glycoprotein Triggers NK Cell Cytotoxicity and Increases Binding of the Activating NK Cell Receptor PILRβ.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 26 11 2018
accepted: 17 01 2019
pubmed: 1 2 2019
medline: 19 11 2019
entrez: 1 2 2019
Statut: epublish

Résumé

Natural killer (NK) cells are components of the innate immunity and are key players in the defense against virus-infected and malignant cells. NK cells are particularly important in the innate defense against herpesviruses, including alphaherpesviruses. Aggravated and life-threatening alphaherpesvirus-induced disease has been reported in patients with NK cell deficiencies. NK cells are regulated by a diversity of activating and inhibitory cell surface receptors that recognize specific ligands on the plasma membrane of virus-infected or malignant target cells. Although alphaherpesviruses have developed several evasion strategies against NK cell-mediated attack, alphaherpesvirus-infected cells are still readily recognized and killed by NK cells. However, the (viral) factors that trigger NK cell activation against alphaherpesvirus-infected cells are largely unknown. In this study, we show that expression of the gB glycoprotein of the alphaherpesvirus pseudorabies virus (PRV) triggers NK cell-mediated cytotoxicity, both in PRV-infected and in gB-transfected cells. In addition, we report that, like their human and murine counterpart, porcine NK cells express the activating receptor paired immunoglobulin-like type 2 receptor beta (PILRβ), and we show that gB expression triggers increased binding of recombinant porcine PILRβ to the surfaces of PRV-infected cells and gB-transfected cells.

Identifiants

pubmed: 30700600
pii: JVI.02107-18
doi: 10.1128/JVI.02107-18
pmc: PMC6430535
pii:
doi:

Substances chimiques

Glycoproteins 0
Membrane Glycoproteins 0
Receptors, Natural Killer Cell 0
Viral Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

J Virol. 2010 Sep;84(17):8664-72
pubmed: 20573830
Trends Immunol. 2007 May;28(5):201-6
pubmed: 17403615
J Virol. 2009 May;83(9):4520-7
pubmed: 19244335
Arch Virol. 1995;140(6):1137-46
pubmed: 7611884
Virology. 1959 Apr;7(4):394-407
pubmed: 13669311
Cold Spring Harb Perspect Biol. 2018 Oct 1;10(10):
pubmed: 29254978
J Gen Virol. 1996 May;77 ( Pt 5):987-90
pubmed: 8609496
Cold Spring Harb Perspect Biol. 2018 Oct 1;10(10):
pubmed: 29254976
Semin Immunol. 2014 Apr;26(2):152-60
pubmed: 24582551
J Immunol. 1984 Aug;133(2):647-52
pubmed: 6610707
J Leukoc Biol. 2018 Jan;103(1):129-140
pubmed: 29345060
Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):231-8
pubmed: 21496407
Curr Opin Virol. 2016 Feb;16:15-23
pubmed: 26590692
Nat Rev Immunol. 2012 Mar 22;12(4):239-52
pubmed: 22437937
J Virol. 2015 Nov 18;90(3):1522-33
pubmed: 26581992
J Allergy Clin Immunol. 2013 Sep;132(3):515-525
pubmed: 23993353
J Infect Dis. 2007 Apr 15;195(8):1160-8
pubmed: 17357052
Nat Med. 2012 Dec;18(12):1827-34
pubmed: 23178246
J Exp Med. 1983 May 1;157(5):1544-61
pubmed: 6189940
J Immunol. 1984 Jul;133(1):368-75
pubmed: 6609988
Cold Spring Harb Perspect Biol. 2018 Oct 1;10(10):
pubmed: 29254979
J Pediatr. 2005 Mar;146(3):423-5
pubmed: 15756234
Trends Immunol. 2015 Sep;36(9):536-46
pubmed: 26272882
Cell. 2008 Mar 21;132(6):935-44
pubmed: 18358807
Eur J Immunol. 2018 Jan;48(1):50-65
pubmed: 28960320
J Immunol. 1984 Oct;133(4):2206-14
pubmed: 6206157
Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8221-6
pubmed: 24843130
J Immunol. 2000 Aug 1;165(3):1197-209
pubmed: 10903717
Immunology. 1996 Aug;88(4):577-85
pubmed: 8881760
Physiol Genomics. 2006 Nov 27;27(3):201-18
pubmed: 16926269
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16118-23
pubmed: 25352670
Clin Transl Immunology. 2018 Jan 31;7(1):e1010
pubmed: 29484187
J Exp Med. 2004 Feb 16;199(4):525-33
pubmed: 14970179
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
J Virol. 2000 Aug;74(15):7137-45
pubmed: 10888654
Curr Opin Immunol. 2016 Jun;40:43-50
pubmed: 27065088
J Virol. 2004 May;78(10):5279-87
pubmed: 15113909
J Virol. 2002 Jul;76(13):6845-51
pubmed: 12050399
J Immunol. 2008 Feb 1;180(3):1686-93
pubmed: 18209065

Auteurs

Steffi De Pelsmaeker (S)

Laboratory of Immunology, Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

Evelien Dierick (E)

Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

Barbara Klupp (B)

Friedrich-Loeffler-Institut, Institute of Molecular Virology and Cell Biology, Greifswald-Insel Riems, Germany.

Thomas C Mettenleiter (TC)

Friedrich-Loeffler-Institut, Institute of Molecular Virology and Cell Biology, Greifswald-Insel Riems, Germany.

Claudia Cantoni (C)

Department of Experimental Medicine and Center of Excellence for Biomedical Research, University of Genoa and IRCCS Instituto Giannina Gaslini, Genoa, Italy.

Massimo Vitale (M)

UOC Immunologia, Ospedale Policlinico San Martino, Genoa, Italy.

Herman W Favoreel (HW)

Laboratory of Immunology, Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium Herman.Favoreel@UGent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH